Management of Elderly Colorectal Cancer Patients: A Comprehensive Review Encompassing Geriatric Assessment.

Cancers (Basel) · 2025 · PMC12564925 · PMID 41154394

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.1800

boldest claim

The sentences

a positive trendp = 0.051so close (0.05 < p ≤ 0.1)

In the RAISE trial evaluating ramucirumab added to second-line FOLFIRI following progression to bevacizumab plus an oxaliplatin based treatment, the addition of the anti-VEGFR2 agent significantly prolonged survival in the overall population, with a positive trend among the elderly (≥65 years, HR for PFS 0.82, p = 0.051; HR for OS 0.85, p = 0.16).

also in 11,005 other papers

showed a trendp = 0.18not close (p > 0.1)

5.1 months; HR 0.53, p < 0.0001) and showed a trend toward improved OS (20.7 vs. 16.8 months, p = 0.18).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.